Kalubalen shari'a na tarayya suna da an wajabta na ɗan lokaci Babban kasuwancin gwamnatin Biden, ma'aikacin kiwon lafiya, da kuma ɗan kwangila na tarayya na Covid-19. Duk da waɗannan umarnin da ke ci gaba da zama na farko na rigakafin covid-19, an riga an ba da "gyare-gyare" da ke ba da rigakafin cutar covid-19, a matsayin misali, ga New Mexico. ma'aikatan kiwon lafiya, da Jami'ar Massachusetts-Amherst dalibai.
Dr. Allon Friedman na kwanan nan Rubutun Brownstone, yana ambaton bazuwar, bayanan gwaji masu sarrafawa akan rigakafin farko na covid-19, ya nuna, “The Pfizer da kuma Moderana gwaje-gwajen sun nuna cewa a cikin ƙananan haɗarin yawan jama'a (wanda ke lissafin yawancin al'umma) allurar COVID-19 ba sa rage mace-mace." Friedman kammala, "Saboda haka, umarnin [covid-19] alluran rigakafi, waɗanda ke da tsada mai yawa kuma suna rarrabuwar kawuna, magani ne mafi muni fiye da cutar."
Me ya sa Dr. Friedman ya dogara keɓance-kuma ba shakka-kan bazuwar, bayanan gwaji da aka sarrafa don tabbatar da ƙarshensa? Kusan shekaru sittin da suka gabata (a cikin 1963) Campbell da Stanley sun buga littafin su na seminal kan hanyoyin bincike mai taken "Na'urorin Gwaji da Quasi-Gwaji don Bincike.” Wannan aikin, wanda ya tsara zane-zanen bincike tun daga lokacin ya nuna manyan barazanar da ke tattare da ingancin hakan ana kaucewa, na musamman, ta hanyar gwajin da bazuwar sarrafawa- ƙirar gwaji ta gaskiya.
Nazari na lura da duk sauran ƙirar ƙira waɗanda ba su da alaƙa da ƙungiyoyin sarrafawa, waɗanda suka kira "gwaji-gwaji" suna cike da sanannun masu binciken son zuciya suna ƙoƙarin sarrafawa, bayan gaskiyar, tare da iyakacin nasara. Mafi muni har yanzu ba za a iya warwarewa ba, rashin sanin ra'ayin da ba a san shi ba wanda tsarin bazuwar, shi kaɗai, ke da alhakin. Guyatt da abokan aiki, a cikin 2008 British Medical Journal takarda"GRADE: yarjejeniya mai tasowa akan ƙimar ingancin shaida da ƙarfin shawarwari”, sabunta da ƙarfafa waɗannan ra'ayoyin, daidai da ba da fifiko mafi girma ga bazuwar, shaidar gwaji mai sarrafawa.
A ranar Juma'a, Nuwamba 19, 2021, Daraktan CDC Dr. Walensky amincewa da faɗaɗa shawarwarin Kwamitin Ba da Shawarar CDC akan Ayyukan rigakafi (ACIP) waɗanda ke haɓaka (kashi na uku) allurai za a ba da su ga duk manya masu shekaru 18, da waɗanda suka girmi, waɗanda suka karɓi allurai na biyu na Pfizer ko Moderna mRNA na biyu, aƙalla watanni 6 a baya.
Abin da bazuwar, shaidar gwaji da aka sarrafa shi ne tushen wannan “hukunce-hukuncen gaba ɗaya,” touted by Dr. Walensky?
Ko da yake ƙanana biyu, da aka buga, bazuwar, gwaji na sarrafa wuribo-ɗaya a ciki masu karbar dashen koda, da wani a cikin a yawan jama'a-bayyana ingantattun martanin rigakafin rigakafi ga masu haɓakawa, shawarar CDC ta ta'allaka ne akan wani babban, unpublished Pfizer bazuwar, gwajin gwaji na asibiti mai sarrafa wuribo.
Wata guda kafin CDC ta faɗaɗa shawarwarin ƙarfafawa, Pfizer's "sakamakon gwaji na bazuwar ta hanyar sakin labarai" sun kasance. bayar (10/21/21). Mutum ~10,000, gwajin ƙarfafa rigakafin rigakafin cutar covid-19, wanda ke sarrafa placebo, bayar da raguwar 95.6% a cikin cututtukan cututtuka na covid-19 (watau 109 a cikin rukunin placebo; 9 a cikin rukunin da aka haɓaka), bayan tsaka-tsakin watanni 2.5 na biyo baya. Sanarwar ta kuma hada da wannan muhimmin al'amari:
"Abubuwan da aka lura da ingancin maganin rigakafi na 95.6% (95% CI: 89.3, 98.6) yana nuna raguwar kamuwa da cuta a cikin rukunin da aka haɓaka tare da ƙungiyar da ba ta haɓaka ba a cikin waɗancan. ba tare da shaidar kamuwa da cutar SARS-CoV-2 da ta gabata ba. "
Nuwamba 19, 2021, Bayanin ACIP na Pfizer's Dr. John Perez ya haɗa da isassun bayanai game da kamuwa da cuta kafin kamuwa da cuta don kammala abubuwan ƙarfafawa ba su rage cututtukan covid-19 ba dangane da placebo a cikin wannan rukunin da ke da alaƙa da asibiti, ƙaramin rukuni mai tasowa. Lissafi masu sauƙi (dangane da nunin faifai daga shafuffuka na 16 da 17) sun nuna alamun cutar covid-2 guda 19 ne kacal a tsakanin mahalarta gwaji 524 da ke da tarihin kamuwa da cutar SARS-CoV-2 da suka gabata, 1/275 wanda ya karɓi masu haɓakawa, da 1/249 da aka ba da allurar placebo (p=0.944 ya canza zuwa +0.038% domin mako.
Bugu da ƙari, CDC's Dr. Oliver, a cikin nazarinta na ACIP (p. 25) na bayanan gwaji na Pfizer, sun yarda cewa a cikin cikakken rukunin ~ 10,000 babu asibiti-19 ko mace-mace, kuma babu bayanai don tantance duk wani tasiri akan watsawar SARS-CoV-2.
Waɗannan binciken sun ƙunshi ƙarancin shaidar gwaji bazuwar kan "tasirin" masu haɓakawa-a zahiri. m akan mafi kyawun sakamako na asibiti na cutar covid-19 mai tsanani da mace-mace. Ko da yuwuwar tasirin masu haɓakawa akan watsa SARS-CoV-2 ya kasance ba a magance shi ba.
Cikin sauri tara bayanai yana ba da shawara mai ƙarfi kafin kamuwa da cutar ta covid-19, “kariya ta halitta,” ta fi ƙarfi, sassauƙa, da jurewa fiye da keɓantaccen rigakafin rigakafin cutar-19. Bayanan gwaji na Pfizer na covid-19 sun tabbatar da masu haɓakawa babu fa'ida wajen hana kamuwa da cutar covid-19 tsakanin wadanda ke da rigakafi na dabi'a.
Idan aka ba da waɗannan binciken gabaɗayan gwajin bazuwar game da masu haɓaka rigakafin rigakafin cutar covid-19-rashin ko da raguwar ɗan gajeren lokaci a cikin masu kamuwa da cuta mai sauƙi-19 a cikin waɗanda ke da rigakafi na halitta, kuma babu wani bayanan da ke tabbatar da cewa masu haɓakawa sun hana kamuwa da COVID-19 asibiti, mace-mace, ko watsa SARS-CoV-2 - babu ma'ana, hujja na tushen hujja don rigakafin cutar covid-19.
-
Andrew Bostom, MD MS, ƙwararren ƙwararren gwaji ne na asibiti da kuma cututtukan cututtuka, wanda a halin yanzu shine Likitan Bincike a Cibiyar Kula da Farko ta Jami'ar Brown don Kulawa na Farko da Rigakafin Asibitin Kent-Memorial a Rhode Island.
Duba dukkan posts
